MAIN RESULTS
By day 21 median crying times were signifi cantly lower in the intervention than in the control group and were 35 (IQR 85) min/day and 90 (IQR 148) min/day, respectively (see table 1) .
Additionally, by day 21, a signifi cantly greater proportion of infants in the intervention group were responders (50% reduction in crying time since the start; see table 2). Sources of funding BioGaia AB Stockholm, Sweden O ne of paediatrics' hoariest of old chestnuts, 'colic' was destined to meet the new universal panacea on the block at some point: probiotics now have several Cochrane paediatric reviews to their name. These include, among others, reports of their purported benefi ts in infective diarrhoea 1 (insuffi cient evidence), eczema 2 (no benefi t) and preventing preterm labour 3 (insuffi cient evidence).
ABSTRACTED FROM
This study appears robust and to have been conducted along standard randomised controlled trial lines. On face value, it worked well, with crying times in the intervention group being one half of those in the controls by 1 week of supplementation and one third by 3 weeks. In terms of mechanistic explanantion, the accompanying 'faecology' underpinned a number of hypothetical microbiological and immunological mechanisms but the study was insuffi ciently powered to test the association between coliform load and symptom severity.
If you sense my reserve, let me explain. First, the infants ranged in age from 2 weeks to 4 months. This heterogeneity raises the possibility of a variety of causes for their crying. Unfortunately, the sample size is insuffi cient to allow a subanalysis by age strata.
Second, all the babies were breast fed and as the microfl ora of formula fed infants is inherently different, the generalisability of the intervention comes into question.
Third, the follow-up stopped at 3 weeks when the intervention period ended. We have no idea whether the purported benefi ts lasted beyond this time.
Fourth, I wonder about the pragmatics of management. Many such babies in the UK, for better or worse, are 'labelled' as having gastro-oesophageal refl ux (GOR) or milk protein intolerance and treatment is started, often empirically. In this study, only one of 50 babies was excluded for GOR, suggesting that it is considered less readily in Italy than in the UK.
What then are the implications for practice? Perhaps a week's trial of probiotics in a screaming baby whose parents report neither vomiting nor colitis or eczema is reasonable before venturing down the usual avenues? I don't pretend to know the answer. The only defi nite is that all babies slowly get better from 'whatever-it-is' that makes them cry (daily crying time halved in the control group over 3 weeks), so parents can be confidently reassured that there is an end in sight.
I'm prepared to believe that a proportion will become 'happier' faster with probiotics, although this study doesn't tell me which ones.
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